DGAP-News: ATOSS Software AG / Key word(s): Half Year Results/Quarter Results ATOSS Software AG: Growth continues with the best half-year in the company's history; strong order intake sustained, outlook positive 22.07.2014 / 08:00 --------------------------------------------------------------------- ATOSS Software AG: Growth continues with the best half-year in the company's history; strong order intake sustained, outlook positive ATOSS Software AG remains on course for continuing growth after posting new record figures for the first half of 2014. With sales up 7 percent at EUR 18.8 million, operating profits (EBIT) were 10 percent higher at EUR 4.7 million. The margin on sales came in at 25 percent compared with 24 percent last year. The workforce management specialist has again succeeded in intensifying its dynamic growth and profitability. During the reporting period, ATOSS recorded a continuous increase in demand for its solutions, with orders received for software licenses coming in 52 percent higher at EUR 5.4 million. The company successfully acquired numerous new enterprise customers in the medical and retail sectors in particular. Against this background, the Management Board expects the sustained positive development in business to continue in the current second half of 2014. Munich, July 22, 2014 For the ninth year in succession ATOSS Software AG has recorded a highly gratifying development in sales and earnings. The company once again has new record figures to report, not least the volume of orders received for software licenses which amounted to EUR 5.4 million, some 52 percent higher than the figure of EUR 3.6 million for the first half of last year. Orders on hand for software licenses as of June 30, 2014 accordingly increased from EUR 3.6 million to EUR 4.7 million, constituting an excellent basis for the remainder of financial year 2014. ATOSS is recording continuous growth spanning products, markets and sectors and is steadily broadening its customer base with sustained effect with the acquisition of prominent new customers. The company's verticalization strategy, consistently developed over a period of years, is proving particularly successful. While overall sales revenues rose from EUR 17.5 million to EUR 18.8 million, sales of software licenses - the driving force behind the company's business model - climbed 9 percent in the first half of 2014 to stand at EUR 4.1 million. There was a similarly consistent positive trend in software maintenance, too, with sales up 7 percent at EUR 7.5 million. As a result, software sales in total amounted to EUR 11.7 million, representing an unchanged proportion of 62 percent of consolidated revenues. In view of the positive order situation, ATOSS also recorded above-average growth in consulting, with sales rising 12 percent to EUR 4.9 million, representing 26 percent of turnover. Hardware, too, profited from the successful development of the core software business, with sales coming in at EUR 1.7 million (previous year EUR 1.5 million). All of the figures quantifying the company's earnings developed even more strongly than the sales figures. Operating profits (EBIT) for the first half of 2014 were 10 percent higher at EUR 4.7 million. And whereas earnings per share last year were substantially influenced by exceptional factors among the financial results and amounted to EUR 0.12 per share, this year has seen a marked improvement, with ATOSS reporting EPS of EUR 0.88 as of June 30, 2014. Net income rose correspondingly from EUR 0.5 million to EUR 3.5 million. Despite paying a dividend totaling EUR 2.9 million (EUR 0.72 per share) at the beginning of May, thanks to the excellent development in business ATOSS was able to report liquidity up 47 percent at EUR 15.3 million. The continuing strong customer interest in ATOSS solutions - impressively demonstrated by the orders received in the past half-year - underscores the company's outstanding future prospects. The Management Board regards the latest record figures as an incentive for the future and expects the highly positive development to be sustained in the current second half and therefore also in financial year 2014 as a whole, as the company continues on the path to further growth. CONSOLIDATED OVERVIEW AS PER IFRS: 6-MONTH COMPARISON IN 000 EUR <pre> 01.01.2- Proportion of 01.01.2- Proportion of Change 014 013 Total sales 2014 / - revenues - Total sales 2013 30.06.2- 30.06.2- revenues 014 013* Sales 18,760 100% 17,531 100% 7% Software 11,681 62% 10,860 62% 8% Software 4,144 22% 3,794 22% 9% licenses Software 7,537 40% 7,066 40% 7% maintenance Consulting 4,945 26% 4,422 25% 12% Hardware 1,681 9% 1,462 8% 15% Miscellaneous 453 3% 787 5% -42% EBITDA 4,958 26% 4,540 26% 9% EBIT 4,697 25% 4,256 24% 10% EBT 5,114 27% 442 3% >100% Net earnings 3,482 19% 460 3% >100% Cash flow 2,699 14% 2,790 16% -3% Liquidity (1/2) 15,325 10,418 47% EPS (in euro) 0.88 0.12 >100% Employees (3) 295 280 5% </pre> CONSOLIDATED OVERVIEW AS PER IFRS: QUARTERLY COMPARISON IN 000 EUR <pre> Q2/14 Q1/14 Q4/13* Q3/13* Q2/13* Sales 9,107 9,653 9,025 8,949 8,840 Software 5,771 5,910 5,617 5,369 5,585 Software licenses 2,002 2,142 1,965 1,779 2,025 Software maintenance 3,769 3,768 3,652 3,590 3,560 Consulting 2,450 2,495 2,375 2,165 2,264 Hardware 631 1,050 768 1,126 569 Miscellaneous 255 198 264 289 422 EBITDA 2,296 2,662 2,094 2,373 2,322 EBIT 2,170 2,527 1,946 2,230 2,186 EBIT margin in % 24% 26% 22% 25% 25% EBT 2,270 2,844 1,385 2,493 -1,962 Net earnings 1,514 1,968 835 1,724 -1,290 Cash flow -1,279 3,979 -186 5,658 297 Liquidity (1/2) 15,325 19,493 15,249 16,177 10,418 EPS (in EUR] 0.38 0.50 0.21 0.43 -0.32 Employees (3) 295 293 289 280 280 </pre> (1) Cash and cash equivalents, other current and non-current financial assets (sight deposits, gold) as of the qualifying date, adjusted to exclude borrowings (loans); (2): Dividend of EUR 3.62 per share on 29.04.2013 (TEUR 14,395) and dividend of EUR 0,72 per share on 02.05.2014 (TEUR 2,863); (3): at the end of the quarter/half year * adjusted for the effects of IAS 19 R Upcoming dates: 12.08.2014 Publication of the six months' statements 21.10.2014 Press release announcing nine months' statements 14.11.2014 Publication of the nine months' statements 24.-26.11.2014 German Equity Forum, Frankfurt ATOSS Software AG is a provider of consulting, software and professional services in the field of demand-oriented personnel planning, and ranks as a forward-thinking pioneer in the workforce management sector. The company offers solutions for enterprises of all sizes, whatever their requirement scenarios. ATOSS solutions are renowned for maximum functionality and modern JAVA technology, offering users the benefits of total platform independence. Established in 1987 and meanwhile listed on the stock market, the company generated sales of around EUR 36 million in financial year 2013. Currently the deployments of around 2.8 million workers employed by more than 4,500 customers are managed with ATOSS solutions. The company's software products are in use in 31 countries and eight languages. Customers include enterprises such as ALDI SÃD, Coca-Cola, Deutsche Bahn, Edeka, Klinikum Ingolstadt, Klinikum Rosenheim, Lufthansa, MEYER WERFT, Schmitz Cargobull, Sixt, Stadt Regensburg and W.L. Gore & Associates. Further information: www.atoss.com Contact ATOSS Software AG Christof Leiber / Member of the Management Board Am Moosfeld 3, D-81829 Munich Tel.: +49 (0) 89 4 27 71 - 0 Fax: +49 (0) 89 4 27 71 - 100 investor.relations@atoss.com End of Corporate News --------------------------------------------------------------------- 22.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: ATOSS Software AG Am Moosfeld 3 81829 München Germany Phone: +49 (0)89 4 27 71-0 Fax: +49 (0)89 4 27 71-100 E-mail: investor.relations@atoss.com Internet: www.atoss.com ISIN: DE0005104400 WKN: 510440 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 278514 22.07.2014
DGAP-News: ATOSS Software AG: Growth continues with the
Top 10 Most Recent News Articles
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup
An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....
Continue ReadingTop 5 Most Recently Viewed Articles
Exploring Kearney's 2025 Global Cities Report Insights
Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...
Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce
Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...
Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook
Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...
Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism
Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...
Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations
Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...
Continue Reading